+

WO2008005248A2 - Amplification en chaîne par polymérase en temps réel dans des micro-canaux - Google Patents

Amplification en chaîne par polymérase en temps réel dans des micro-canaux Download PDF

Info

Publication number
WO2008005248A2
WO2008005248A2 PCT/US2007/014863 US2007014863W WO2008005248A2 WO 2008005248 A2 WO2008005248 A2 WO 2008005248A2 US 2007014863 W US2007014863 W US 2007014863W WO 2008005248 A2 WO2008005248 A2 WO 2008005248A2
Authority
WO
WIPO (PCT)
Prior art keywords
channel
pcr
marker
reaction
temperature
Prior art date
Application number
PCT/US2007/014863
Other languages
English (en)
Other versions
WO2008005248A3 (fr
Inventor
Kenton C. Hasson
Gregory A. Dale
Hiroshi Inoue
Original Assignee
Canon U.S. Life Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/505,358 external-priority patent/US7629124B2/en
Application filed by Canon U.S. Life Sciences, Inc. filed Critical Canon U.S. Life Sciences, Inc.
Priority to EP07796482.3A priority Critical patent/EP2046988A4/fr
Priority to JP2009518241A priority patent/JP2009542210A/ja
Publication of WO2008005248A2 publication Critical patent/WO2008005248A2/fr
Publication of WO2008005248A3 publication Critical patent/WO2008005248A3/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502715—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502769—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by multiphase flow arrangements
    • B01L3/502784—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by multiphase flow arrangements specially adapted for droplet or plug flow, e.g. digital microfluidics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L7/00—Heating or cooling apparatus; Heat insulating devices
    • B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
    • B01L7/525—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples with physical movement of samples between temperature zones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06—Fluid handling related problems
    • B01L2200/0673—Handling of plugs of fluid surrounded by immiscible fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/14—Process control and prevention of errors
    • B01L2200/143—Quality control, feedback systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
    • B01L2300/087—Multiple sequential chambers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/18—Means for temperature control
    • B01L2300/1805—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks
    • B01L2300/1822—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks using Peltier elements
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/18—Means for temperature control
    • B01L2300/1838—Means for temperature control using fluid heat transfer medium
    • B01L2300/1844—Means for temperature control using fluid heat transfer medium using fans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/18—Means for temperature control
    • B01L2300/1838—Means for temperature control using fluid heat transfer medium
    • B01L2300/185—Means for temperature control using fluid heat transfer medium using a liquid as fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0415—Moving fluids with specific forces or mechanical means specific forces electrical forces, e.g. electrokinetic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
    • B01L2400/0487—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L7/00—Heating or cooling apparatus; Heat insulating devices
    • B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples

Definitions

  • the present invention relates to methods for amplifying nucleic acids in micro- channels. More specifically, the present invention relates to methods for performing a real-time polymerase chain reaction (PCR) in a continuous-flow microfluidic system and to methods for monitoring real-time PCR in such systems.
  • PCR polymerase chain reaction
  • nucleic acids are central to medicine, forensic science, industrial processing, crop and animal breeding, and many other fields.
  • One of the most powerful and basic technologies to detect small quantities of nucleic acids is to replicate some or all of a nucleic acid sequence many times, and then analyze the amplification products. PCR is perhaps the most well-known of a number of different amplification techniques.
  • PCR 10004 J PCR is a powerful technique for amplifying short sections of DNA. With PCR, one can quickly produce millions of copies of DNA starting from a single template DNA molecule.
  • PCR includes a three phase temperature cycle of denaturation of DNA into single strands, annealing of primers to the denatured strands, and extension of the primers by a thermostable DNA polymerase enzyme. This cycle is repeated so that there are enough copies to be detected and analyzed. In principle, each cycle of PCR could double the number of copies. In practice, the multiplication achieved after each cycle is always less than 2. Furthermore, as PCR cycling continues, the buildup of amplified DNA products eventually ceases as the concentrations of required reactants diminish.
  • Real-time PCR refers to a growing set of techniques in which one measures the buildup of amplified DNA products as the reaction progresses, typically once per PCR cycle. Monitoring the accumulation of products over time allows one to determine the efficiency of the reaction, as well as to estimate the initial concentration of DNA template molecules.
  • Real-Time PCR An Essential Guide, K. Edwards et al., eds., Horizon Bioscience, Norwich, U.K. (2004).
  • Hydrolysis probes use the polymerase enzyme to cleave a reporter dye molecule from a quencher dye molecule attached to an oligonucleotide probe.
  • Conformation probes utilize a dye attached to an oligonucleotide, whose fluorescence emission changes upon the conformational change of the oligonucleotide hybridizing to the target DNA.
  • sample containers for these instruments are closed tubes which typically require at least a 10 ⁇ l volume of sample solution. If the lowest concentrations of template DNA detectable by a particular assay were on the order of one molecule per microliter, the detection limit for available instruments would be on the order of tens of targets per sample tube. Therefore, in order to achieve single molecule sensitivity, it is desirable to test smaller sample volumes, in the range of 1 -1000 nl.
  • Enzelberger et al. (U.S. Patent No. 6,960,437) describe a microfluidic device that includes a rotary channel having three temperature zones. A number of integrated valves and pumps are used to introduce the sample and to pump it through the zones in a rotary fashion.
  • Knapp et al. (U.S. Patent Application Publication No. 2005/0042639) describe a microfluidic device capable of single molecule amplification. A planar glass chip with several straight parallel channels is disclosed. A mixture of target DNA and PCR reagents is injected into these channels. In a first embodiment, the channels are filled with this mixture and flow is stopped. Then the entire length of the channels is thermally cycled.
  • the channels are imaged in order to detect regions of fluorescence where DNA has been amplified.
  • the PCR mixture flows continuously through the amplification zone as the temperature is cycled, and fluorescence is detected downstream of the amplification zone. Different degrees of amplification are achieved by altering the time spent in cycling, through changing distance traveled under cycling, and the like. It is worth noting that this method varies conditions (such as cycles experienced) for separate consecutive sample elements, rather than monitoring the progress of individual sample elements over time. [0013J None of this art has combined single target molecule sensitivity with real-time reaction monitoring capability in a continuous flow device. Thus, a need exists for robust high throughput methods of real-time PCR that can be performed efficiently and accurately with small sample volumes. It would be desirable that the methods have single target molecule sensitivity, use lower quantities of PCR reagents and use less energy for temperature cycling. The present invention provides these and other features that will be apparent upon review of the description of the invention.
  • the present invention relates to methods for amplifying nucleic acids in micro- channels. More specifically, the present invention relates to methods for performing a real-time polymerase chain reaction (PCR) in a continuous-flow microfluidic system and to methods for monitoring real-time PCR in such systems.
  • PCR polymerase chain reaction
  • the present invention provides a method of performing real-time PCR comprising the steps of: a) continuously moving a bolus of test solution containing real- time PCR reagents in a channel; b) moving a carrier-fluid in the channel, sequentially alternating with a test bolus; c) cycling the temperature in a defined section of the channel in order to achieve PCR; and d) measuring the intensity of the fluorescent signal at a plurality of locations along the defined section of the channel.
  • the channel is a micro-channel or a microfluidic channel, such that the dimensions of the channel are small enough to allow for the amplification and detection of a single DNA molecule originally present in the test solution.
  • the test solution is substantially the same as the carrier fluid, except that it comprises all the necessary real-time PCR reagents.
  • the real-time PCR reagent mixture may include PCR primers, dNTPs, polymerase enzymes, salts, buffers, surface-passivating agents, and the like.
  • the real-time PCR mixture may include a non-specific fluorescent DNA detecting molecule, a sequence-specific fluorescent DNA probe or a marker.
  • the carrier fluid is an immiscible fluid. The purpose of the carrier fluid is to deter transfer of material from one test bolus to another. Another purpose of the carrier fluid is to provide a distinguishable transition between boluses that may be used to track the fluid flow in the channel.
  • the carrier fluid may include a marker.
  • the temperature is cycled using a thermal transfer element along the defined section of the channel.
  • the thermal transfer element cycles the temperature in the entire defined section of the channel. That is, a constant temperature zone is used to provide the thermal cycling.
  • an appropriately programmed computer controls the temperature cycling of the thermal transfer element.
  • the temperature of the thermal transfer element is detected and fed back to the computer.
  • heating and cooling are applied to a length of the channel (the reaction zone) such that its temperature follows a PCR profile in time.
  • the test boluses are pumped through this reaction zone at a flow rate (speed) such that the number of PCR cycles required is achieved during the time the bolus flows from the upstream end to the downstream end of the reaction zone.
  • the intensity of the fluorescent signal is measured at a specific time and/or temperature during the PCR temperature cycle. In an additional embodiment, the intensity of the fluorescent signal is measured once during each PCR cycle. In a further embodiment, the plurality of locations at which the intensity of the fluorescent signal is measured is the entire defined section of the channel. In another embodiment, the data concerning the intensity of the fluorescent signal is processed by an appropriately programmed computer. In another embodiment, an image of at least one fluorescent signal along the length of the channel is made. In a further embodiment, the image capture is performed repeatedly on consecutive temperature cycling periods. The image may be created or the intensity of the fluorescent signal measured using a multiple-pixel array detector. A stationary mechanism or a scanning mechanism or both may be used to capture the image.
  • the present invention provides a method for performing real-time PCR that includes monitoring the average flow speed of the liquid in a channel.
  • the method comprises the steps as set forth in the first aspect and further comprises the step of: e) measuring the average flow speed of the fluid in the channel.
  • average flow speed of the fluid is measured by comparing sequential images of the reaction-dependent fluorescent signal from the channel.
  • the average flow speed of the fluid is measured by comparing sequential images of a marker (i.e., a reaction independent marker) in the channel.
  • a marker i.e., a reaction independent marker
  • the use of the marker has the advantage that if the real-time PCR signal is not detectable, the fluid flow would still be detectable.
  • potential markers are dyes, semiconductor quantum dots, polymer microbeads, scattering metal particles, microbubbles, and the like known to skilled artisans.
  • the marker is present in the test solution. If the marker is present in the test solution, it should not adversely affect any PCR chemical reactions. In another embodiment, the marker is present in the carrier fluid.
  • the marker is a separate bolus in series with test boluses.
  • the marker is resolvable from the fluorescent signal, such as by excitation wavelength, emission spectrum, lifetime, and the like well known in the art.
  • the data concerning the sequential images of the intensity of the fluorescent signal or of the marker is processed by an appropriately programmed computer.
  • the average flow speed is determined by comparing images taken from consecutive PCR cycles.
  • the flow speed can be measured using a reaction zone entrance detector and a volume flow rate meter. Flow speed could be estimated, for example, by knowing the dimensions of the channel and measuring the volume flow rate.
  • the present invention provides a method for performing real-time PCR that includes monitoring the flow speed of the liquid in a channel and adjusting the flow speed as necessary to control the duration of the PCR cycling experienced by a test solution or test sample.
  • the method comprises the steps as set forth in the second aspect and further comprises the step of: f) adjusting the flow speed of the fluid to control the duration of the PCR cycling.
  • the flow speed is monitored and adjusted such that the desired number of PCR cycles is completed while the test solution is moving through the defined section of the channel. That is, the flow speed is adjusted to determine the duration of the PCR cycling.
  • this monitoring and adjustment is performed by an appropriately programmed computer.
  • the flow rate is adjusted by regulating the pressure at the input end of the channel. In an additional embodiment, the flow rate is adjusted by regulating the pressure regulated vacuum at the output end of the channel. In another embodiment, the flow rate is adjusted by regulating a pump, such as a syringe pump.
  • the present invention provides method for monitoring the progress of a polymerase chain reaction in a channel comprising the steps of: a) moving a bolus of test solution containing real-time PCR reagents in a channel; b) moving a carrier fluid in said channel, sequentially alternating with a test bolus; c) cycling the temperature in a defined section of the channel in order to achieve PCR; d) capturing an image of a reaction-dependent fluorescence signal along a section of the channel; e) measuring the average flow speed in the channel; and f) relating position of the test bolus to the number of temperature cycles experienced by a test bolus from the average flow rate.
  • the average flow speed is measured by comparing sequential images of the reaction-dependent fluorescent signal from the channel. In a second embodiment, the average flow speed is measured by comparing sequential images of a reaction-independent flow marker from the channel.
  • the reaction- independent flow marker may be (i) pre-mixed in the test bolus, (ii) introduced to the channel as a bolus alternating with the test bolus or (iii) pre-mixed in the carrier fluid.
  • scattered light from the reaction-independent flow marker is resolvable from the reaction-dependent fluorescence by wavelength spectrum. In an alternative embodiment, scattered light from the reaction-independent flow marker is resolvable from the reaction- dependent fluorescence on the basis of fluorescence lifetime.
  • the reaction-independent flow marker is further used to determine the flow dispersion of the test bolus.
  • the image of reaction-dependent fluorescence is captured at least once per PCR cycle. In one embodiment, the image of reaction-dependent fluorescence is captured sequentially by scanning a length of the channel on a time scale shorter than the duration of one PCR cycle. In an alternative embodiment, the image of reaction-dependent fluorescence is captured by acquiring signal from multiple points along the channel simultaneously.
  • the flow speed measurements are part of a feedback loop for regulating the flow speed. In a further embodiment, the flow speed is measured through detecting a sample bolus entrance into and exit from a defined section of the channel.
  • the present invention provides a method for monitoring the progress of a polymerase chain reaction in a channel, comprising the steps of: a) moving a bolus of test solution containing real-time PCR reagents in a channel; b) moving a carrier fluid in the same channel, sequentially alternating with a test bolus; c) applying spatial temperature zones along the channel to achieve PCR; d) monitoring the fluorescence signal at fixed spatial locations along the channel corresponding to fixed points in the PCR cycle; e) measuring the average flow speed of the fluid in the channel; and f) adjusting the flow rate in order to control the timing of the PCR cycle.
  • the temperature is cycled using a thermal transfer element along portions of the channel.
  • the thermal transfer element cycles the temperature in the portions of the channel.
  • an appropriately programmed computer controls the temperature cycling of the thermal transfer element.
  • the temperature of the thermal transfer element is detected and fed back to the computer.
  • heating and cooling are applied to portions of the channel such that a PCR temperature profile is followed.
  • the test boluses are pumped through this reaction zone at a flow rate (speed) such that the number of PCR cycles required is achieved during the time the bolus flows from the upstream end to the downstream end of the reaction zone.
  • the present invention provides systems and/or kits adapted for practicing the methods described herein.
  • the systems and/or kits can include system instructions (e.g., embodied in a computer or in a computer readable medium, e.g., as system software) for practicing any of the method steps herein.
  • Fluid handling elements for storing, transferring, aliquotting, or diluting samples, e.g., microfluidic handling elements, and detector elements can also be components of the systems and kits herein.
  • packaging materials, integration elements e.g., instrument cases, power supplies, etc.
  • instructions for using the systems and kits and the like can be features of the invention.
  • the invention provides a system that includes a microfluidic device comprising one or more amplification channels each configured to thermocycle one or more test solutions.
  • a thermal transfer element for cycling the temperature along a defined section of the channel(s) is also included.
  • the thermal transfer element is integral with or proximal to the microfluidic device.
  • a source of illumination integral with or proximal to the microfluidic device is also included, where the source of illumination is configured to illuminate the channel(s).
  • a detector integral with or proximal to the microfluidic device is also included, where the detector is configured to detect the amplification products and/or marker in the channel(s).
  • the detector can independently detect signals from two or more detectable markers with different signals; e.g., a detector that can simultaneously detect fluorescent or other emissions at two or more wavelength ranges.
  • the system includes one or more elements for controlling the flow rate of the continuously moving test solution and carrier fluid in the channel (s), as well as system instruction or software for monitoring and controlling the flow rate in order to control the timing of each PCR cycle.
  • the system includes a sensor to detect the temperature of the thermal transfer element and to provide feedback information for controlling the temperature cycles.
  • the system also includes system software for generating and processing data, such as timing the detection of the amplified products and/or marker, monitoring location of test solutions in the channel(s) and the like.
  • the system may also include a dilution module that dilutes the sample into multiple test solutions, as well as system instructions that direct the dilution module to aliquot the sample into a plurality of test solutions.
  • the dilution module may be integral with or proximal to the microfluidic device.
  • the system optionally comprises software with instructions for performing any of the method steps described herein.
  • the system can include statistical or probabilistic system software that performs one or more statistical or probabilistic analysis of signals received from one or more of the test solutions subjected to thermocycling.
  • the statistical or probabilistic analysis can include Poisson analysis, Monte Carlo analysis, application of a genetic algorithm, neural network training, Markov modeling, hidden Markov modeling, multidimensional scaling, PLS analysis, and/or PCA analysis.
  • the statistical or probabilistic analysis optionally comprises quantitatively determining a concentration, proportion, or number of the nucleic acids of interest in the sample.
  • the system also optionally includes fluid handling or storage features such as sample storage modules that store the samples until they are to be diluted by the dilution module, a sample retrieval module that retrieves the sample from the sample storage module and delivers it to the dilution module, or the like. These features are optionally designed to provide for continuous flow of fluid (e.g., comprising the sample) through the system (thereby providing for higher sample throughput).
  • the system may also include means and system software for analyzing the amplified product.
  • the system may include system software that correlates a reproducible signal shape, length, width, volume or area occupied by the amplification products, as detected by the detector, to (a) the number of copies of the nucleic acid of interest present in one of the test solutions, or to the number of copies of the nucleic acid of interest present in the sample, or both or (b) an identification of the amplification product(s) present in the sample or (c) any other analytical parameters known and used in the art. [0028] Many of the above methods or systems can be used in combination. Additional features of the invention will become apparent upon review of the following description.
  • Figure 1 shows a block diagram of a real-time PCR architecture in accordance with one embodiment of the present invention.
  • Figure 2 shows a schematic illustration of a real-time PCR microfluidic system in accordance with one embodiment of the present invention.
  • Figures 3A and 3B shows a sensor output image with data processing from the system of Figure 2.
  • FIG. 4 shows a schematic illustration of a real-time PCR microfluidic system in accordance with another embodiment of the present invention.
  • FIG. 5 shows sensor output data from the system of Figure 4 in accordance with the present invention.
  • Figure 6 shows a system that is useful for quantitative PCR in real-time in a microfluidic device in accordance with yet another embodiment of the present invention.
  • Figure 7 shows a process diagram illustrating a mode of operation according to one embodiment of the invention.
  • Figure 8A is an image of a fluorescent signal showing the growth of PCR products in microfluidic channels under flow conditions.
  • Figure 8B is a plot of the intensity of the marker along a microchannel from Figure
  • Figure 9A is an image of a fluorescent signal showing the growth of PCR products in microfluidic channels under flow conditions.
  • Figure 9B is a plot of the intensity of the green signal along a microchannel from
  • the present invention relates to methods for amplifying nucleic acids in micro- channels. More specifically, the present invention relates to methods for performing a real-time polymerase chain reaction (PCR) in a continuous-flow microfluidic system and to methods for monitoring real-time PCR in such systems.
  • PCR polymerase chain reaction
  • FIG. 1 illustrates a block diagram of a real-time PCR architecture in accordance with one embodiment of the present invention.
  • the system includes a test solution reservoir 101, which as described above, may be a reservoir containing multiple test solutions, such as a microtiter plate in which each well contains different test solutions, e.g., test samples.
  • the system further includes a carrier fluid reservoir 102.
  • the test solution is substantially the same as the carrier fluid, except that the test solution comprises all the necessary real-time PCR reagents.
  • the real-time PCR reagent mixture may include PCR primers, dNTPs, polymerase enzymes, salts, buffers, surface-passivating agents, and the like.
  • the real-time PCR mixture may include a non-specific fluorescent DNA detecting molecule, a sequence-specific fluorescent DNA probe or a marker.
  • the carrier fluid is an immiscible fluid (such as an oil, a tluorinated liquid, or any other nonaqueous or hydrophobic solvent). The purpose of the carrier fluid is to deter transfer of material from one test bolus to another. Another purpose of the carrier fluid is to provide a distinguishable transition between boluses that may be used to track the fluid flow in the channel.
  • the carrier fluid may include a marker.
  • MicroChannel 103 may be a single microchannel or it may be one of several microchannels that are part of a microfluidic device (such as shown in Figures 2, 4 and 6).
  • Switch 104 is under control of a main control and processing computer 105 such that the carrier fluid and the test solution are sequentially alternately introduced into microchannel 103.
  • the volume of the test solution and carrier fluid that is introduced into microchannel 103 is selected such that there is minimal blending between them during movement through microchannel 103.
  • a multitude of reactions in series (or sequential reactions) can thus be carried out in the same microchannel 103 as a result of the continuous movement of different test solutions through microchannel 103 each separated by the carrier fluid. If microchannel 103 is one of several microchannels in a microfluidic device, then a multitude of reactions can also be carried out in parallel in the microchannels of the microfluidic device.
  • the flow rate of the carrier fluid and test solution through microchannel 103 is controlled by pump mechanism 106. Pump mechanism 106 is under control of main control and processing computer 105 in order to regulate the flow rate of the test solution and the carrier fluid in microchannel 103. The flow rate is regulated such that a desired number of PCR cycles are performed as the test solution passes through microchannel 103.
  • Pump mechanism 106 can regulate the flow rate of the test solution and carrier fluid by positive pressure at the upstream side or inlet of microchannel 103 or by negative pressure at the downstream side or outlet of microchannel 103.
  • the pressure difference is approximately 1 psi, although other pressure differences may be utilized.
  • the length of microchannel 103 is suitable for the completion of the desired number of PCR cycles such as, for example, 10 to 50 cycles of PCR, or any number in between, as the test solution moves through the reaction zone of microchannel 103.
  • the reaction zone of microchannel 103 is the region of the microchannel in which the temperature is cycled for conducting the PCR cycles. Typically, 25-30, 25-35, 25-40, 30-35, 30-40 or 35-40 PCR cycles are performed for standard amplification reactions.
  • the length of microchannel 103 to accomplish the desired number of PCR cycles is also dependent on the volume of test solution and carrier fluid that are sequentially alternately moved through microchannel 103. For example, if the reaction zone is 40 mm, then the minimum volume of test solution would occupy 1 mm in the reaction zone of microchannel 103, and the maximum volume of test solution would occupy 20 mm in the reaction zone of microchannel 103. Thus, in this non-limiting example, a minimum of 1 sample and a maximum of 20 samples could be amplified as the test solution moves through the reaction zone of microchannel 103.
  • the microchannel length and sample volumes can be selected to amplify any number of samples.
  • a temperature control system 107 is included in the system to control and cycle the temperature to produce suitable temperatures for the PCR cycles as the test solution moves through microchannel 103. Suitable temperatures for the PCR cycles are well known to skilled artisan and may include a first temperature in the range of about 85° C to about 100° C, a second temperature in the range of about 20° C to about 70° C and a third temperature in the range of about 55° C to about 80° C. Temperature control system 107 is integral with or proximal to microchannel 103 or to the microchannels of a microfluidic device. Temperature control system 107 includes heaters 108, coolers 109, temperature sensors 1 10 and a temperature controller 1 1 1.
  • Temperature controller 1 11 collects temperature information from the temperature sensors 1 10 and generates control signals based on the temperature information. The control signals are sent to the heaters 108 or coolers 109 to cycle the temperature in microchannel 103 for the desired PCR cycles. Temperature controller 1 1 1 is under control of main control and processing computer 105 so that the temperature is cycled such that the desired number of PCR cycles is performed as the test solution moves through microchannel 103. The different PCR reactions in the different test solutions follow one after another in microchannel 103 in a serial manner due to the continuous flow in microchannel 103.
  • the heating and cooling may be accomplished by blowing air of the appropriate temperatures.
  • the heating and cooling may be accomplished by circulating water or fluid baths.
  • the heating and cooling may be accomplished by Peltier-effect elements which are well known to the skilled artisan. Junctions of different metals, which are crossed by an electric current, make it possible to cool or heat a small surface. A temperature probe on the Peltier element makes it possible to regulate the power, which is proportional to the electrical intensity, and thus makes it possible to regulate the temperature.
  • a metal block is used as a thermal transfer element and includes a thermoelectric cooler in contact with the metal block.
  • This metal block can be made of any metal (or metal alloy) having suitable thermal transfer properties such as, for example, aluminum. In order to reduce backscatter of light from the metal block it is preferably painted black or anodized.
  • the temperatures for the PCR cycles can equilibrate at suitable time intervals for this thermal transfer unit. For example, the temperatures for the PCR cycles can equilibrate within approximately 1 -2 seconds or even faster.
  • temperature control system 107 cycles the temperature in an entire defined section of microchannel 103, i.e., that section of microchannel 103 in which the PCR cycles are performed.
  • This defined section of microchannel 103 is also known as the reaction zone.
  • a constant temperature zone is used to provide the thermal cycling.
  • An appropriately programmed computer controls the temperature cycling of the thermal transfer element.
  • heating and cooling are applied to a length of the channel (the reaction zone) such that its temperature follows a PCR profile in time.
  • the test boluses are pumped through this reaction zone at a flow rate (speed) such that the number of PCR cycles required is achieved during the time the bolus flows from the upstream end to the downstream end of the reaction zone.
  • temperature control system 107 applies spatial temperature zones along microchannel 103 to achieve a polymerase chain reaction.
  • the temperature is cycled using a thermal transfer element along portions of the microchannel 103 or the microchannels of a microfluidic device.
  • the thermal transfer element cycles the temperature in portions of microchannel 103.
  • An appropriately programmed computer controls the temperature cycling of the thermal transfer element.
  • heating and cooling are applied to portions of the channel such that a PCR temperature profile is followed.
  • the test boluses are pumped through this reaction zone at a flow rate (speed) such that the number of PCR cycles required is achieved during the time the bolus flows from the upstream end to the downstream end of the reaction zone.
  • An optical imaging system 1 12 is included in one embodiment of the present invention to detect the amplification product and to monitor the flow rate of the test solution in microchannel 103.
  • the optical imaging system 1 12 is a fluorescent imaging system that preferably includes one or more excitation sources 1 13, one or more optics/filters 1 14 and one or more detectors 1 15.
  • excitation sources 1 13 generate light at desired wavelengths to excite the labels used for detecting the amplification products during realtime PCR and/or to detect markers that may be present to monitor the flow rate of the test solution in microchannel 103.
  • Optics/filters 114 are used to form a beam of light and/or to direct the light from excitation sources 1 13 to the appropriate positions on the microchannel 103.
  • Optics/filters 1 14 are also used to filter the light to exclude light of undesired wavelengths or to reduce backscatter from reaching detectors 115.
  • the desired wavelengths to excite the labels used in real-time PCR will depend on the precise labels and/or markers used, e.g., intercalating dyes, molecular beacons, quantum dots or TaqMan ® probes, which wavelengths are well known to skilled artisans.
  • the emission wavelengths of the precise labels and/or markers are well known to skilled artisans.
  • Detectors 1 15 detect the emission wavelengths of the excited labels and/or markers and measure the intensity of the emitted light.
  • Optical imaging system 112 preferably is able to distinguish between multiple microchannels in a microfluidic device.
  • Optical imaging system 112 is under control of main control and processing computer 105 which directs the optical/fluorescence imaging system 1 12 to measure the intensity of the emitted light at desired time intervals, such as, for example, at least once during each PCR cycle at a plurality of locations in microchannel 103 or in the microchannels of a microfluidic device.
  • Detectors 115 generate a signal or an image of the intensity of the emitted light and direct it to main control and processing computer 105 for analysis of the amplification product and for monitoring the flow rate of the test solution.
  • Detectors 1 15 may include multiple-pixel array detectors (such as a CCD detector) and/or discrete single-pixel or non-imaging detectors.
  • Detectors 1 15 may be integral with or proximal to microchannel 103 or to the microchannels of a microfluidic device. Detectors 1 15 may be stationary or may be scanning. The detectors 1 15 should have appropriate resolution for obtaining meaningful results and for monitoring of fluid flow in microchannel 103, particularly because the fluid is continuously moving in microchannel 103.
  • the real-time PCR mixture may include a non-specific fluorescent DNA detecting molecule (such as an intercalating dye), a sequence-specific fluorescent DNA probe (such as a molecular beacon, a TaqMan ® probe or a quantum dot probe), or a flow marker (such as a quantum dot), and the carrier fluid may include a flow marker.
  • the optical imaging system 1 12 is utilized to detect the intensity of the fluorescence from the DNA detecting molecule or the probe (i.e., the intensity of the fluorescent signal) and/or to detect the fluorescence of the marker.
  • the fluorescence of the marker can be used to delineate the test solution from the carrier fluid and can also be used to determine and monitor the flow speed of the test solution or carrier fluid.
  • the intensity of the fluorescent signal can be used to detect amplified product, to determine the quantity of amplified product, to determine the number of original molecules present in the test solution, and the like as well known to a skilled artisan for real-time PCR.
  • the intensity of the fluorescent signal can also be used to determine and monitor the flow speed of the test solution.
  • the intensity of the fluorescent signal is measured (e.g., an image of the fluorescent signal is taken) at a specific time and/or temperature during the PCR temperature cycle. In another embodiment, the intensity of the fluorescent signal is measured once during each PCR cycle.
  • the optimal time to capture the image depends on the chemistry utilized. For example, if an intercalating dye is used to detect amplified product, the image should be captured at the end of the extension phase of the PCR cycle. If a TaqMan ® probe is used to detect the amplified product, the image could be captured at any time during the PCR cycle.
  • Main control and processing computer 105 can be programmed to take the image at the time and temperature desired.
  • the intensity of the fluorescent signal is measured at a plurality of locations.
  • the plurality of locations at which the intensity of the fluorescent signal is measured may be different sections of the microchannel.
  • the plurality of locations at which the intensity of the fluorescent signal is measure may be the entire defined section (i.e., reaction zone) of the microchannel.
  • an image of at least one fluorescent signal along the length of the channel is made.
  • the image capture is performed repeatedly on consecutive temperature cycling periods. The image may be created or the intensity of the fluorescent signal measured using a multiple-pixel array detector (such as a CCD or CMOS image sensor) or a single pixel detector.
  • Fluorescent light may be collected using large field-of-view imaging optics and/or small field-of-view optics such as a fiber-optic/lens combination.
  • a stationary mechanism or a scanning mechanism or both may be used to capture the image.
  • the data concerning the intensity of the fluorescent signal is processed by an appropriately programmed computer.
  • Post-PCR analyzer 116 may include any analytical technique that can be used on PCR amplification products. Such techniques include, but are not limited to, sequencing, electrophoresis, probing, melt curve analysis, and the like.
  • FIG. 2 Examples of systems useful for real-time PCR in microchannels in accordance with the present invention are shown schematically in Figures 2, 4 and 6.
  • a real-time PCR system 200 is illustrated with a microfluidic device 201 that contains multiple microchannels. Because there is an effect of gravity on the fluid in the microchannels, microfluidic device 201 is preferably oriented such that the test and carrier fluids flow in a generally horizontal direction. However, microfluidic device 201 may be oriented in such that the carrier and test fluids flow in other directions including the vertical direction.
  • a thermal transfer element is located proximal to microfluidic device 201.
  • the optical imaging system includes an illumination laser 202 and a beam forming lens 203 for illuminating the microchannels in microfluidic device 201 with the appropriate excitation wavelength(s).
  • the optical imaging system further includes a filter 204 for filtering the emission wavelength(s) and reducing backscatter and a multiple-pixel array detector 205.
  • the real-time PCR system 200 may also optionally include a lens 207.
  • a sensor output image with data processing using this system is shown in Figures 3A and 3B.
  • Figure 3 A shows a two dimensional image of 8 parallel - microfluidic channels filled with 100 nM FAM fluorescent dye.
  • Figure 3B shows a profile plot of the region of interest box 301 of Figure 3 A. .
  • a system 400 for real-time PCR is illustrated with a microfluidic device 401 that contains multiple microchannels.
  • a thermal transfer element (not shown) is proximal to microfluidic device 401.
  • the optical imaging system includes an illumination laser 402 and a beam forming lens 404 for illuminating the microchannels in microfluidic device 401 with the appropriate excitation wavelength(s).
  • the optical imaging system further includes a filter 405 for filtering the emission wavelength(s) and reducing backscatter and a CCD detector 406.
  • the real-time PCR system 400 may also optionally include a lens 403. Sensor output data from a 512 pixel linear CCD array sensor using this system is shown in Figure 5.
  • realtime PCR system 600 includes a microfluidic device 602 which preferably includes multiple microchannels and a thermal element (not shown) located proximal to microfluidic device 602.
  • This embodiment further includes a light source 608 that is capable of emitting light at multiple wavelengths such as, for example, red and blue light, for providing multi-color excitation light to the channels in microfluidic device 602.
  • the light source 608 includes multiple LEDs which emit light at different wavelengths.
  • the real-time PCR system 600 further includes an excitation filter 607 and a dual bandpass interference filter 605 that passes light at the multiple excitation wavelengths (such as red light and blue light).
  • the system 600 also includes a lens 601 for collecting the emitted light, for example, from a flourophore in the amplification product and a different fluorophore in a flow marker, and directing it to detector 604.
  • an emission filter 606 is also provided for blocking excitation light and passing the fluorescent light from the flourophores.
  • Detector 604 can be a multiple pixel array which is capable of multicolor sensing such as, for example, CMOS image sensor.
  • the system 600 further includes a color filter array 610 for arranging RGB colors on the detector 604 which enables simultaneous imaging of multiple colors.
  • the color filter array 610 could be, for example, a Bayer filter.
  • the systems described herein are specifically adapted for methods of performing realtime PCR in a microchannel and methods for monitoring the progress of a polymerase chain reaction in a microchannel.
  • a bolus of test solution is continuously moved in the microchannel.
  • the test solution contains real-time PCR reagents as described above.
  • a carrier fluid is continuously moved in the microchannel.
  • the carrier fluid sequentially alternates with a test bolus.
  • the temperature is cycled in a defined section of the microchannel in order to achieve PCR.
  • the intensity of the fluorescent signal is measured at a plurality of locations along the defined section of the microchannel.
  • a method for performing real-time PCR comprises the steps of: a) continuously moving a bolus of test solution containing real-time PCR reagents in a channel; b) moving a carrier-fluid in the channel, sequentially alternating with a test bolus; c) cycling the temperature in a defined section of the channel in order to achieve PCR; and d) measuring the intensity of the fluorescent signal at a plurality of locations along the defined section of the channel.
  • the temperature is cycled using a thermal transfer element along the defined section of the channel.
  • the thermal transfer element cycles the temperature in the entire defined section of the channel. That is, a constant temperature zone is used to provide the thermal cycling.
  • an appropriately programmed computer controls the temperature cycling of the thermal transfer element, hi one embodiment, the temperature of the thermal transfer element is detected and fed back to the computer. In accordance with these embodiments, heating and cooling are applied to a length of the channel (the reaction zone) such that its temperature follows a PCR profile in time.
  • the intensity of the fluorescent signal is measured at a specific time and/or temperature during the PCR temperature cycle.
  • the intensity of the fluorescent signal is measured once during each PCR cycle.
  • the plurality of locations at which the intensity of the fluorescent signal is measured is the entire defined section of the channel.
  • the data concerning the intensity of the fluorescent signal is processed by an appropriately programmed computer.
  • an image of at least one fluorescent signal along the length of the channel is made.
  • the image capture is performed repeatedly on consecutive temperature cycling periods. The image may be created or the intensity of the fluorescent signal measured using a multiple-pixel array detector. A stationary mechanism or a scanning mechanism or both may be used to capture the image.
  • the performance of real-time PCR includes monitoring the flow rate (flow speed) of the fluid in the microchannel.
  • the liquid may be the test solution or the carrier fluid.
  • a method for performing real-time PCR comprises the steps of: a) continuously moving a bolus of test solution containing real-time PCR reagents in a channel; b) moving a carrier-fluid in the channel, sequentially alternating with a test bolus; c) cycling the temperature in a defined section of the channel in order to achieve PCR; d) measuring the intensity of the fluorescent signal at a plurality of locations along the defined section of the channel and e) measuring the average flow rate of the fluid in the channel.
  • average flow speed of the fluid is measured by comparing sequential images of the reaction-dependent fluorescent signal from the channel.
  • the average flow speed of the fluid is measured by comparing sequential images of a marker (i.e., a reaction-independent marker) in the channel.
  • a marker i.e., a reaction-independent marker
  • the marker has the advantage that if the real-time PCR signal is not detectable, the fluid flow would still be detectable.
  • potential markers are dyes, semiconductor quantum dots, polymer microbeads, scattering metal particles, microbubbles, and the like known to skilled artisans.
  • the marker is present in the test solution. If the marker is present in the test solution, it should not adversely affect any PCR chemical reactions.
  • the marker is present in the carrier fluid.
  • the marker is. a separate bolus in series with test boluses.
  • the marker is resolvable from the fluorescent signal, such as by excitation wavelength, emission spectrum, lifetime, and the like well known in the art.
  • the data concerning the sequential images of the intensity of the fluorescent signal or of the marker is processed by an appropriately programmed computer.
  • the average flow speed is determined by comparing images taken from consecutive PCR cycles.
  • the flow rate can be measured using a reaction zone entrance detector and a flow speed meter. Flow speed could be estimated, for example, by knowing the dimensions of the channel and measuring the volume flow rate.
  • the performance of real-time PCR includes monitoring the flow rate (flow speed) of the fluid in the microchannel and adjusting the flow rate as necessary to control the duration of the PCR cycling experienced by a test solution.
  • a method for performing real-time PCR comprises the steps of: a) continuously moving a bolus of test solution containing real-time PCR reagents in a channel; b) moving a carrier-fluid in the channel, sequentially alternating with a test bolus; c) cycling the temperature in a defined section of the channel in order to achieve PCR; d) measuring the intensity of the fluorescent signal at a plurality of locations along the defined section of the channel; e) measuring the average flow speed of the fluid in the channel; and f) adjusting the flow rate of the fluid to control the duration of the PCR cycling.
  • the flow rate is monitored and adjusted such that the desired number of PCR cycles is completed while the test solution is moving through the defined section of the channel. That is, the flow rate is adjusted to determine the duration of the PCR cycling. In another embodiment, this monitoring and adjustment is performed by an appropriately programmed computer, such as main control and processing computer 105. In a further embodiment, the flow rate is adjusted by regulating the pressure at the input end of the channel. In an additional embodiment, the flow rate is adjusted by regulating the pressure regulated vacuum at the output end of the channel. In another embodiment, the flow rate is adjusted by regulating a pump, such as a syringe pump.
  • the flow rate is monitored and adjusted so that the desired number of PCR cycles is performed as the test solution moves through the reaction zone of the microchannel. For example, if the reaction zone of the microchannel is 30 mm and it is desired to perform 30 PCR cycles, then the flow rate is monitored so that a flow rate of 1 mm/cycle is achieved and maintained. Since each PCR cycle may be on the order of 30-60 seconds, the flow speed in the microchannel is fairly slow in this example.
  • 00671 Figure 7 is a process diagram illustrating a mode of operation for regulating the flow speed of the fluid as moves through the channels according to one embodiment of the invention. In this embodiment, a closed loop feedback is used to regulate the flow speed.
  • the fluid in the channels is moved by activating a regulated pressure pump, such as, for example, pump mechanism 106, at a pump pressure set point.
  • a PCR temperature profile is executed over a defined section of a channel.
  • the system acquires one or more images of the contents of the channel. These image data and the time of acquisition are stored to a database for subsequent analysis, such as, for example, the main control and processing computer 105. If two sequential images are not available, the temperature cycling and image acquisition repeat without changing the pressure set point. If two sequential images are available, they may be compared to determine how far the fluid has moved along the channel. Dividing the average displacement by the time elapsed gives an average flow speed.
  • the pump pressure set point is adjusted automatically so that the desired flow speed obtained, and the process is repeated. If there is no difference between the measured flow speed and the desired flow speed, the pump pressure set point remains the same, and the process is repeated.
  • a method for monitoring the progress of a polymerase chain reaction in a microchannel comprises the steps of: a) moving a bolus of test solution containing real-time PCR reagents in a microchannel; b) moving a carrier fluid in said microchannel, sequentially alternating with a test bolus; c) cycling the temperature in a defined section of the microchannel in order to achieve PCR; d) capturing an image of a reaction-dependent fluorescence signal along a section of the microchannel; e) measuring the average flow rate in the microchannel; and f) relating position of the test bolus to the number of temperature cycles experienced by a test bolus from the average flow rate.
  • the average flow rate is measured by comparing sequential images of the reaction-dependent fluorescent signal from the channel.
  • the average flow rate is measured by comparing sequential images of a reaction-independent flow marker from the channel.
  • the reaction-independent flow marker may be (i) pre-mixed in the test bolus, (ii) introduced to the channel as a bolus alternating with the test bolus or (iii) pre- mixed in the carrier fluid.
  • scattered light from the reaction-independent flow marker is resolvable from the reaction-dependent fluorescence by wavelength spectrum.
  • scattered light from the reaction-independent flow marker is resolvable from the reaction-dependent fluorescence on the basis of fluorescence lifetime.
  • the reaction-independent flow marker is further used to determine the flow dispersion of the test bolus.
  • the image of reaction-dependent fluorescence is captured at least once per PCR cycle. In one embodiment, the image of reaction- dependent fluorescence is captured sequentially by scanning a length of the channel on a time scale shorter than the duration of one PCR cycle. In an alternative embodiment, the image of reaction-dependent fluorescence is captured by acquiring signal from multiple points along the channel simultaneously.
  • the flow rate measurements are part of a feedback loop for regulating the flow rate. In a further embodiment, the flow rate is measured through detecting a sample bolus entrance into and exit from a defined section of the channel.
  • a method for monitoring the progress of a polymerase chain reaction in a microchannel comprises the steps of: a) moving a bolus of test solution containing real-time PCR reagents in a microchannel; b) moving a carrier fluid in the same microchannel, sequentially alternating with a test bolus; c) applying spatial temperature zones along the microchannel to achieve PCR; d) monitoring the fluorescence signal at fixed spatial locations along the microchannel corresponding to fixed points in the PCR cycle; e) measuring the average flow rate of the fluid in the microchannel; and f) adjusting the flow rate in order to control the timing of the PCR cycle.
  • the temperature is cycled using a thermal transfer element along portions of the channel.
  • the thermal transfer element cycles the temperature in the portions of the channel.
  • an appropriately programmed computer controls the temperature cycling of the thermal transfer element, such as main control and processing computer illustrated in Figure 1.
  • the temperature of the thermal transfer element is detected and fed back to the computer.
  • heating and cooling are applied to portions of the channel such that a PCR temperature profile is followed.
  • the test boluses are pumped through this reaction zone at a flow rate (speed) such that the number of PCR cycles required is achieved during the time the bolus flows from the upstream end to the downstream end of the reaction zone.
  • the present invention also provides systems and/or kits adapted for practicing the above described methods.
  • the systems and/or kits can include system instructions (e.g., embodied in a computer or in a computer readable medium, e.g., as system software) for practicing any of the method steps herein.
  • Fluid handling elements for storing, transferring, aliquoltirig, or diluting samples, e.g., microfluidic handling elements, and detector elements can also be components of the systems and kits herein.
  • packaging materials, integration elements e.g., instrument cases, power supplies, etc.
  • instructions for using the systems and kits and the like can be features of the invention.
  • the invention provides a system that includes a microfluidic device comprising one or more amplification channels (microchannels) each configured to thermocycle one or more test solutions.
  • a thermal transfer element for cycling the temperature along a defined section of the channel(s) is also included.
  • the thermal transfer element is integral with or proximal to the microfluidic device.
  • a source of illumination integral with or proximal to the microfluidic device is also included, where the source of illumination is configured to illuminate the channel(s).
  • a detector integral with or proximal to the microfluidic device is also included, where the detector is configured to detect the amplification products and/or marker in the channel(s).
  • the detector can independently detect signals from two or more detectable markers with different signals; e.g., a detector that can simultaneously detect fluorescent or other emissions at two or more frequencies, such as the system illustrated in Figure 6.
  • the system includes one or more elements for controlling the flow rate of the continuously moving test solution and carrier fluid in the channel(s), as well as system instruction or software for monitoring and controlling the flow rate in order to control the timing of each PCR cycle.
  • the system includes a sensor to detect the temperature of the thermal transfer element and to provide feedback information for controlling the temperature cycles.
  • the system also includes system software for generating and processing data, such as timing the detection of the amplified products and/or marker, monitoring location of test solutions in the channel(s) and the like.
  • the system may also include a dilution module that dilutes the sample into multiple test solutions, as well as system instructions that direct the dilution module to aliquot the sample into a plurality of test solutions.
  • the dilution module may be integral with or proximal to the microfluidic device.
  • the system optionally comprises software with instructions for performing any of the method steps described herein.
  • the system can include statistical or probabilistic system software that performs one or more statistical or probabilistic analysis of signals received from one or more of the test solutions subjected to thermocycling.
  • the statistical or probabilistic analysis can include Poisson analysis, Monte Carlo analysis, application of a genetic algorithm, neural network training, Markov modeling, hidden Markov modeling, multidimensional scaling, partial least square (PLS) analysis, and/or principle component analysis (PCA).
  • the statistical or probabilistic analysis optionally comprises quantitatively determining a concentration, proportion, or number of the nucleic acids of interest in the sample. These statistical evaluations can be used to correlate abundance or proportions to diagnosis or prognosis associated with the diagnosis or prognosis.
  • the system also optionally includes fluid handling or storage features such as sample storage modules that store the samples until they are to be diluted by the dilution module, a sample retrieval module that retrieves the sample from the sample storage module and delivers it to the dilution module, or the like. These features are optionally designed to provide for continuous flow of fluid (e.g., comprising the sample) through the system (thereby providing for higher sample throughput).
  • the system may also include means and system software for analyzing the amplified product.
  • the system may include system software that correlates a reproducible signal shape, length, width, volume or area occupied by the amplification products, as detected by the detector, to (a) the number of copies of the nucleic acid of interest present in one of the test solutions, or to the number of copies of the nucleic acid of interest present in the sample, or both or (b) an identification of the amplification product(s) present in the sample or (c) any other analytical parameters known and used in the art.
  • the nucleic acid of interest that can be amplified and detected in the methods of the invention can be essentially any nucleic acid.
  • the sequences for many nucleic acids and amino acids are available. No attempt is made to identify the hundreds of thousands of known nucleic acids, any of which can be detected in the methods of the invention.
  • Common sequence repositories for known nucleic acids include GenBank EMBL, DDBJ and the NCBI. Other repositories can easily be identified by searching the internet.
  • the nucleic acid can be an RNA (e.g., where amplification includes RT-PCR) or DNA (e.g., where amplification includes PCR), or an analogue thereof (e.g., for detection of synthetic nucleic acids or analogues thereof). Any variation in a nucleic acid can be detected, e.g., a mutation, a single nucleotide polymorphism (SNP), an allele, an isotype, a fragment, a full-length nucleic acid, an amplicon, etc. Further, because the present invention is quantitative, one can detect variations in expression levels, fragmentation, or gene copy numbers by the methods.
  • SNP single nucleotide polymorphism
  • the methods of the invention are particularly useful in screening samples derived from patients for the nucleic acids of interest, e.g., from bodily fluids and/or waste from the patient. This is because samples derived from relatively large volumes of such materials can be screened in the methods of the invention (removal of such materials is also relatively noninvasive).
  • the nucleic acids of interest e.g., present in cancer cells
  • whole blood, serum, plasma, stool, urine, vaginal secretions, ejaculatory fluid, synovial fluid, a biopsy, cerebrospinal fluid, and amniotic fluid, sputum, saliva, lymph, tears, sweat, or urine, or the like can easily be screened for rare nucleic acids or fragmentation by the methods of the invention, as can essentially any tissue of interest.
  • samples are typically taken, following informed consent, from a patient by standard medical laboratory methods.
  • nucleic acids Prior to amplification, nucleic acids are optionally purified from the samples by any available method, e.g., those taught in Berger and Kimmel ⁇ Methods in Enzymology 152, Academic Press, Inc., San Diego, Calif., 1987); Sambrook and Russell, Molecular Cloning, 3rd Ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001); Ausubel et al., Current Protocols in Molecular Biology (John Wiley & Sons, updated through 2005).
  • kits are also commercially available for the purification of nucleic acids from cells or other samples (sec, e.g., EasyPrepTM, FlexiPrepTM, both from Pharmacia Biotech; StrataCleanTM from Stratagene; and, QIAprepTM from Qiagen).
  • samples can simply be directly subjected to amplification, e.g., following aliquotting and dilution.
  • One advantage of single molecule detection is that the low concentration of sample components in the reaction can reduce the need for nucleic acid purification. That is, dilution of the sample reduces the abundance of unwanted components at the same time it distributes the nucleic acid of interest into reaction mixtures.
  • nucleic acids of interest to be detected in the methods herein is those involved in cancer.
  • Any nucleic acid that is associated with cancer can be detected in the methods of the invention, e.g.,. those that encode over expressed or mutated polypeptide growth factors (e.g., sis), over expressed or mutated growth factor receptors (e.g., crb-Bl), over expressed or mutated signal transduction proteins such as G-proteins (e.g., Ras), or non-receptor tyrosine kinases (e.g., abl), or over expressed or mutated regulatory proteins (e.g., myc, myb, jun, fos, etc.) and/or the like.
  • polypeptide growth factors e.g., sis
  • over expressed or mutated growth factor receptors e.g., crb-Bl
  • signal transduction proteins such as G-proteins (e.g., Ras), or non-receptor tyrosine kinases (e.
  • nucleic acids of interest are screened for the amount of fragmentation, with high fragmentation generally associated with apoptosis of normal cells and less fragmentation associated, e.g., with sloughing of cancer cells.
  • cancer can often be linked to signal transduction molecules and corresponding oncogene products, e.g., nucleic acids encoding Mos, Ras, Raf, and Met; and transcriptional activators and suppressors, e.g., p53, Tat, Fos, Myc, Jun, Myb, ReI, and/or nuclear receptors.
  • p53 colloquially referred to as the "molecular policeman" of the cell
  • the molecular policeman is of particular relevance, as about 50% of all known cancers can be traced to one or more genetic lesion in p53.
  • 0081 J One class of genes that are relevant to cancer is the class of nuclear hormone receptors, which have been described in detail and the mechanisms by which these receptors can be modified to confer oncogenic activity have been worked out. For example, the physiological and molecular basis of thyroid hormone action is reviewed in Yen ⁇ Physiological Reviews 81: 1097-1142, 2001), and the references cited therein.
  • Known and well characterized nuclear receptors include those for glucocorticoids (GRs), androgens (ARs), mineralocorticoids (MRs), progestins (PRs), estrogens (ERs), thyroid hormones (TRs), vitamin D (VDRs), retinoids (RARs and RXRs), and the peroxisome proliferator activated receptors (PPARs) that bind eicosanoids.
  • GRs glucocorticoids
  • ARs mineralocorticoids
  • PRs progestins
  • ERs estrogens
  • TRs thyroid hormones
  • VDRs vitamin D
  • RARs and RXRs retinoids
  • PPARs peroxisome proliferator activated receptors
  • nucleic acids of interest involved with cancer are those that are diagnostic of colon cancer, e.g., in samples derived from stool.
  • Colon cancer is a common disease that can be sporadic or inherited.
  • the molecular basis of various patterns of colon cancer is known in some detail.
  • germline mutations are the basis of inherited colon cancer syndromes, while an accumulation of somatic mutations is the basis of sporadic colon cancer.
  • a mutation that was previously thought to be a polymorphism may cause familial colon cancer. Mutations of at least three different classes of genes have been described in colon cancer etiology: oncogenes, suppressor genes, and mismatch repair genes.
  • One example nucleic acid encodes DCC (deleted in colon cancer), a cell adhesion molecule with homology to f ⁇ bronectin.
  • An additional form of colon cancer is an autosomal dominant gene, hMSH2 that comprises a lesion. Familial adenomatous polyposis is another form of colon cancer with a lesion in the MCC locus on chromosome #5.
  • DCC deficesion molecule
  • hMSH2 autosomal dominant gene
  • Familial adenomatous polyposis is another form of colon cancer with a lesion in the MCC locus on chromosome #5.
  • DNA entering the colon lumen from a colon tumor cells can remain generally unfragmented. Detecting the presence of a proportion of unfragmented nucleic acids over a certain threshold in a stool specimen can correlate to presence of a colon cancer.
  • Cervical cancer is another target for detection, e.g., in samples obtained from vaginal secretions. Cervical cancer can be caused by the human papilloma virus and has two oncogenes, E6 and E7. E6 binds to and removes p53 and E7 binds to and removes PRB. The loss of p53 and uncontrolled action of E2F/DP growth factors without the regulation of pRB is one mechanism that leads to cervical cancer. Furthermore, as with colon cancer, detecting the presence of a proportion of unfragmented nucleic acids over a certain threshold in a vaginal swab can correlate to the presence of a cervical cancer.
  • retinoblastoma e.g., in samples derived from tears, and Neurofibromatosis Type 1 , e.g. in CSF or via tissue sampling.
  • Many other forms of cancer are known and can be found by detecting, e.g., associated genetic lesions, fragmentation proportions, or absolute concentrations of full-length nucleic acids of interest using the methods of the invention.
  • Cancers that can be detected by detecting appropriate lesions or fragmentation values include cancers of the lymph, blood, stomach, gut, colon, testicles, pancreas, bladder, cervix, uterus, skin, and essentially all others for which an associated genetic lesion or fragmentation threshold exists.
  • nucleic acids from pathogenic or infectious organisms can be detected by the methods of the invention, e.g., for infectious fungi, e.g., Aspergillus, or Candida species; bacteria, particularly E. coli, which serves a model for pathogenic bacteria (and, of course certain strains of which are pathogenic), as well as medically important bacteria such as Staphylococci (e.g., aureus), or Streptococci (e.g., pneumoniae); protozoa such as sporozoa (e.g., Plasmodia), rhizopods (e.g., Entamoeba) and flagellates (Trypanosoma, Leishmania, Trichomonas, Giardia, etc.); viruses such as (+) RNA viruses (examples include Poxviruses e.g., vaccinia; Picornaviruses, e.g.
  • RNA viruses e.g., Rhabdoviruses, e.g., VSV; Paramyxovimses, e.g., RSV; Orthomyxovimses, e.g., influenza; Bunyaviruses; and Arenaviruses
  • dsDNA viruses Reoviruses, for example
  • RNA to DNA viruses i.e., Retroviruses, e.g., HIV and HTLV
  • retroviruses e.g., HIV and HTLV
  • certain DNA to RNA viruses such as Hepatitis B.
  • Single and low copy amplification methods of the invention can be useful in many cases, e.g., in exudates from bacterial infections to identify living (having full length nucleic acids) versus dead and lysed pathogens (having fragmented nucleic acids).
  • nucleic acid encoding enzymes e.g., industrial enzymes
  • amidases amino acid racemases, acylases, dehalogenases, dioxygenases, diarylpropane peroxidases, epimerases, epoxide hydrolases, esterases, isomerases, kinases, glucose isomerases, glycosidases, glycosyl transferases, haloperoxidases, monooxygenases (e.g., p450s), lipases, lignin peroxidases, nitrile hydratases, nitrilases, proteases, phosphatases, subtilisins, transaminase, and nucleases.
  • amidases amino acid racemases, acylases, dehalogenases, dioxygenases, diarylpropane peroxidases, epimerases, epoxide hydrolases, esterases, isomerases, kinases, glucose
  • agriculturally related proteins such as insect resistance proteins (e.g., the Cry proteins), starch and lipid production enzymes, plant and insect toxins, toxin-resistance proteins, Mycotoxin detoxification proteins, plant growth enzymes (e.g., ribulose 1,5-bisphosphate carboxylase/oxygenase), lipoxygenase (LOX), and phosphoenolpyruvate (PEP) carboxylase can also be detected.
  • insect resistance proteins e.g., the Cry proteins
  • starch and lipid production enzymes e.g., plant and insect toxins, toxin-resistance proteins, Mycotoxin detoxification proteins, plant growth enzymes (e.g., ribulose 1,5-bisphosphate carboxylase/oxygenase), lipoxygenase (LOX), and phosphoenolpyruvate (PEP) carboxylase
  • LOX lipoxygenase
  • PEP phosphoenolpyruvate
  • the sample can be aliquotted and/or diluted using standard or microfluidic fluid handling approaches (or combinations thereof)- Standard fluid handling approaches for dilution/aliquotting include, e.g., pipetting appropriate volumes of the sample into microtiter trays and adding an appropriate diluent. These operations can be performed manually or using available high throughput fluid handlers, such as, e.g., those designed to use serially dilute solutions in microtiter trays. High throughput equipment (e.g., incorporating automated pipettors and robotic microtiter tray handling) is preferred, as the present invention contemplates making and using high numbers of aliquots of a sample of interest.
  • standard or microfluidic fluid handling approaches include, e.g., pipetting appropriate volumes of the sample into microtiter trays and adding an appropriate diluent.
  • These operations can be performed manually or using available high throughput fluid handlers, such as, e.g., those designed to use serially dilute solutions in microtiter
  • a conventional high throughput systems can be used in place of, or in conjunction with microfluidic systems (for example, conventional systems can be used to aliquot samples into microtiter trays, from which microfluidic systems can draw materials) in practicing the methods of the invention.
  • microfluidic systems provide a preferred fluid handling and amplification technology that can conveniently be applied to the present invention.
  • samples are drawn into microfluidic devices that comprise networks of microscale cavities (channels, chambers, etc., having at least one dimension less than about 500 ⁇ M in size and often less than about 100 ⁇ M) and the samples are mixed, diluted, aliquotted or otherwise manipulated in the network of cavities (e.g., channels and/or chambers).
  • the microscale device can comprise one or more capillary, in fluid communication with the network, extending outward from a body structure of the microscale device.
  • negative pressure vacuum
  • fluids are drawn into the network from a container (e.g., a well on a microtiter tray).
  • This process can be multiplexed by using a device that comprises multiple capillary channels, permitting many samples to be drawn into the network and processed simultaneously. Alternately, multiple samples can be sequentially drawn into the microfluidic device and routed internally to multiple channels for simultaneous processing and analysis. Sample interfaces with dried samples can also be performed using this basic system, e.g., by partly or completely expelling fluid from the capillary to hydrate samples prior to drawing them into the microfluidic device (the fluid is typically contacted to the samples as a hanging drop on the tip of the capillary and then drawn back into the capillary). For either approach, see also, U.S. Patent Nos. 6,482,364, 6,042,709, 6,287,520 and 6,235,471.
  • any fluid manipulation can be performed in the network using available methods. Details regarding dilution and aliquotting operations in microscale devices can be found in the patent literature, e.g., U.S. Patent Nos. 6,149,870, 5,869,004 and 6,440,722.
  • Samples and components to be mixed/diluted or aliquotted can be brought into the microscale device through pipettor elements or from reaction component reservoirs on the device itself, or, commonly, both.
  • the sample can be brought into the microfluidic device through a pipettor channel and diluted and supplied with common reagents from an on device dilution and/or reagent reservoir(s).
  • Locus specific reagents can be on the device in wells, or stored off the device, e.g., in microtiter plates (in which case they can be accessed by the pipettor channel). Any or all of these operations can be performed in a continuous or stopped flow format.
  • the microfluidic device typically performs several functions, including reaction assembly (assembly of reaction mixtures), thermocycling, and acting as a "cuvette" for an optical system during an imaging (detection) step. In the reaction assembly, the reaction mixture components (particularly magnesium and the enzyme) which get combined at the last second before heating begins are assembled. This is called a "hot start” and provides advantages of specificity.
  • thermocycling the system optionally provides both constant fluid movement and a continuous sequence of temperature changes.
  • a high data rate CCD detector, a multiple-pixel array detector or a fiber-optic ball head lens detector, for example, is useful in providing an adequate dynamic range for methods of quantification.
  • Commercial systems that perform all aspects of fluid handling that can be used in the practice of the present invention are available. Examples include the 250 HTS system and AMS 90 SE from Caliper Life Sciences (Hopkinton, MA).
  • a sample can be diluted equally in each aliquot, or, alternately, the aliquots can be differentially diluted (e.g., a dilution series can be made).
  • the aliquots themselves can be of a volume that is appropriate to the fluid handling approach being used by the system, e.g., on the order of a few microliters for microtiter plates to 100 nL, 10 nL or even 1 nL or less for microfluidic approaches.
  • the aliquots can be selected to have high or low copy numbers of any relevant nucleic acid (e.g., for low copy number aliquots, 50 or fewer, generally 25 or fewer, usually 10 or fewer and often 5 or fewer, 2 or fewer or 1 or fewer copies of the relevant nucleic acid(s)).
  • the number of aliquots generated will depend on the size of the sample and the amount of quantitative information desired by the practitioner. For example, where simple detection of a rare nucleic acid is desired, enough low and/or single copy number aliquots are made of the sample to detect the nucleic acid in one of the aliquots. Where more quantitative information is needed, enough copies are made to provide reliable statistical information, e.g., to a given confidence value.
  • this can include anywhere from 1 aliquot to 10.sup.9 or more aliquots, e.g., 10, 100, 1,000, 10,000, 100,000, 1,000,000, 1 ,000,000,000 or more aliquots.
  • aliquots there is no theoretical limit on the number of aliquots that can be made and assessed for a nucleic acid of interest according to the present invention, though there are practical considerations with respect to the throughput of the system and the size of the sample (the lower the throughput, the fewer aliquots can be analyzed in a given time; the larger the sample size the more aliquots can be made of the sample).
  • reagent usage and concomitant reagent costs
  • the systems of the invention can greatly speed the process of searching many different samples for a nucleic acid of interest.
  • stopped flow approaches simultaneous processing of signals from PCR reactions can be used to speed the process of searching samples for a nucleic acid of interest.
  • about 150 aliquots for each dilution range was sufficient to provide reasonable quantitative information for Poisson statistics for model samples. Obviously, more or fewer aliquots can be used in the methods as well.
  • the methods of the invention include amplifying one or more sequences of a nucleic acid of interest from a sample or aliquot and, optionally, one or more additional nucleic acids.
  • Real time PCR and/or real time reverse transcriptase-PCR e.g., mediated via TaqMan ® probes, molecular beacon-based probes or quantum dot based probes are used to facilitate detection of amplified nucleic acids.
  • fluorescent labels are not to be limited to single species organic molecules, but include inorganic molecules, multi-molecular mixtures of organic and/or inorganic molecules, crystals, heteropolymers, and the like. Suitable fluorescent labels can be provided by, e.g., DNA binding dyes, molecular beacons, TaqMan ® probes or quantum dots.
  • the amplification product (which is double stranded) binds dye molecules in solution to form a complex. With the appropriate dyes, it is possible to distinguish between dye molecules free in solution and dye molecules bound to amplification product.
  • certain dyes fluoresce only when bound to amplification product.
  • suitable dyes include, but are not limited to, LC Green (Idaho Technology, Salt Lake City, Utah), SYBR ® Green, SYBR ® GreenERTM and Pico Green (Invitrogen Corp., Carlsbad, Calif.), ethidium bromide, propidium iodide, chromomycin, acridine orange, Hoechst 33258, Hoechst 33342, Toto-1, Yoyo-1, and DAPl (4',6-diamidino-2-phenylindole hydrochloride). Additional discussion regarding the use of intercalation dyes is provided by Zhu et al. (Anal Chem 66:1941-1948, 1994).
  • a molecular beacon is an oligonucleotide or PNA which, under appropriate hybridization conditions, self-hybridizes to form a stem and loop structure.
  • the MB has a label and a quencher at the termini of the oligonucleotide or PNA; thus, under conditions that permit intra-molecular hybridization, the label is typically quenched (or at least altered in its fluorescence) by the quencher. Under conditions where the MB does not display intra-molccular hybridization (e.g., when bound to a target nucleic acid, e.g., to a region of an amplicon during amplification), the MB label is unquenched.
  • MBs are robust reagents for detecting and quantifying nucleic acids, including in real time, e.g., during PCR, LCR or other nucleic acid amplification reactions (e.g., MBs can be used to detect targets as they are formed).
  • a variety of commercial suppliers produce standard and custom molecular beacons, including Cruachem (cruachem.com), Oswel Research Products Ltd. (UK; oswel.com), Invitrogen Corp. (Carlsbad, Calif.; invitrogen.com), the Midland Certified Reagent Company (Midland, Tex. mcrc.com) and Gorilla Genomics, LLC (Alameda, Calif.).
  • kits which utilize molecular beacons are also commercially available, such as the SentinelTM.
  • Molecular Beacon Allelic Discrimination Kits from Stratagene (La Jolla, Calif.) and various kits from Eurogentec SA (Belgium, eurogentec.com) and Isogen Bioscience BV (The Netherlands, isogen.com).
  • MB components e.g., oligos, including those labeled with fluorophores or quenchers
  • oligos or peptide nucleic acids can be synthesized on commercially available automated oligonucleotide/PNA synthesis machines using standard methods. Labels can be attached to the oligos or PNAs either during automated synthesis or by post-synthetic reactions which have been described before see, e.g., Tyagi and Kramer (Nat Biotechnology 14:303-308, 1996) and U.S. Pat. Nos. 6,037,130 and 5,925,517.
  • Labels/quenchers can be introduced to the oligonucleotides or PNAs, e.g., by using a controlled-pore glass column to introduce, e.g., the quencher (e.g., a 4-dimethylaminoazobenzene-4'-sulfonyl moiety (DABSYL).
  • the quencher e.g., a 4-dimethylaminoazobenzene-4'-sulfonyl moiety (DABSYL).
  • the quencher can be added at the 3' end of oligonucleotides during automated synthesis; a succinimidyl ester of 4-(4'-dimethylaminophenylazo)benzoic acid (DABCYL) can be used when the site of attachment is a primary amino group; and 4-dimethylaminophenylazo- phenyl-4'- maleimide (DABMI) can be used when the site of attachment is a sulphydryl group.
  • DBCYL succinimidyl ester of 4-(4'-dimethylaminophenylazo)benzoic acid
  • DABMI 4-dimethylaminophenylazo- phenyl-4'- maleimide
  • fluorescein can be introduced in the oligos, either using a fluorescein phosphoramadite that replaces a nucleoside with fluorescein, or by using a fluorescein dT phosphoramadite that introduces a fluorescein moiety at a thymidine ring via a spacer.
  • fluorescein dT phosphoramadite that introduces a fluorescein moiety at a thymidine ring via a spacer.
  • iodoacetoamidofluorescein can be coupled to a sulphydryl group.
  • Tetrachlorofluorescein (TET) can be introduced during automated synthesis using a 5'- tetrachloro-fluorescein phosphoramadite.
  • TaqMan ® probes are composed of short (e.g., 20-25 bases) oligodeoxynucleotides that are labeled with two different fluorescent dyes. On the 5' terminus of each probe is a reporter dye, and on the 3' terminus of each probe a quenching dye is found.
  • the oligonucleotide probe sequence can be complementary to an internal target sequence present in a PCR amplicon. When the probe is intact, energy transfer occurs between the two fluorophores and emission from the reporter is quenched by the quencher (fluorescent resonant energy transfer or FRET).
  • the probe is cleaved by 5' nuclease activity of the polymerase used in the reaction, thereby releasing the reporter from the oligonucleotide- quencher and producing an increase in reporter emission intensity.
  • TaqMan probes are oligonucleotides that have a label and a quencher, where the label is released after hybridization and during amplification by the exonuclease action of the polymerase used in amplification. This provides a real time measure of amplification during synthesis.
  • a variety of TaqMan ® reagents are commercially available, e.g., from Applied Biosystems (Division Headquarters in Foster City, Calif.) as well as from a variety of specialty vendors such as Biosearch Technologies (e.g., black hole quencher probes).
  • a quantum dot is a fluorescent semiconductor nanocrystal having a characteristic - spectral emission, which is tunable to a desired energy by selection of the particle size of the quantum dot.
  • the quantum dot emits a characteristic emission spectrum which can be observed and measured spectrophotometrically.
  • the emission spectra of quantum dots have linewidths as narrow as 25-30 nm depending on the size heterogeneity of the sample, and lineshapes that are symmetric, gaussian or nearly gaussian with an absence of a tailing region.
  • the combination of tunability, narrow linewidths, and symmetric emission spectra without a tailing region provides for high resolution of multiply-sized quantum dots within a system and enables researchers to examine simultaneously a variety of biological moieties tagged with quantum dots.
  • the range of excitation wavelengths of the nanocrystal quantum dots is broad and can be higher in energy than the emission wavelengths of all available quantum dots. Consequently, this allows the simultaneous excitation of all quantum dots in a system with a single light source, usually in the ultraviolet or blue region of the spectrum.
  • Quantum dots are also more robust than conventional organic fluorescent dyes and are more resistant to photobleaching than the organic dyes. The use of quantum dots as fluorescent labels of nucleotides is described in Bruchez et al.
  • Multicolor, multiplexed assays are a particular strength of quantum dot bioconjugates.
  • the emission from quantum dot nanocrystals is narrow and symmetric; therefore, overlap with other colors is minimal, yielding less bleed through into adjacent detection channels and attenuated crosstalk and allowing many more colors to be used simultaneously. Since each bioconjugate color is based upon the same underlying material (they differ only in size), the conjugation and use methods for one color are easily extrapolated to all of the different colors, simplifying and speeding assay development.
  • every quantum dot nanocrystal can be excited using a single light source — narrow laser and broad lamp excitation are both useful. Three- or four-color detection no longer requires multiple lasers or laborious alignments and compensations.
  • oligonucleotides include probes, molecular beacons, PNAs, LNAs (locked nucleic acids), etc.
  • synthetic methods for making oligonucleotides are well known.
  • oligonucleotides can be synthesized chemically according to the solid phase phosphoramidite triester method described by Beaucage and Caruthers ⁇ Tetrahedron Letts 22:1859-1862, 1981), e.g., using a commercially available automated synthesizer, e.g., as described in Needham- VanDevanter et al. ⁇ Niicl Acids Res 12:6159-6168, 1984).
  • Oligonucleotides can also be ordered from a variety of commercial sources known to persons of skill. There are many commercial providers of oligo synthesis services, and thus this is a broadly accessible technology. Any nucleic acid can be custom ordered from any of a variety of commercial sources, such as The Midland Certified Reagent Company (mcrc@oligos.com), The Great American Gene Company (www.genco.com), ExpressGen Inc. (www.expressgen.com), Operon Technologies Inc. (Alameda, Calif.) and many others. Similarly, PNAs can be custom ordered from any of a variety of sources, such as PeptidoGenic (pkim@ccnet.com), HTI Bio- products, inc. (www.htibio.com), BMA Biomedicals Ltd (U.K.), Bio-Synthesis, Inc., and many others.
  • Any available method for detecting amplified nucleic acids can be used in the present invention. Common approaches include real time amplification detection with molecular beacons, quantum dots or TaqMan ® probes, detection of intercalating dyes (such as those described above), detection of labels incorporated into the amplified nucleic acids themselves and the like. Amplified nucleic acids (amplicons) can be detected in homogenous (substantially unseparated) reaction mixtures or solutions. [0108] Amplification and detection are commonly integrated in a system comprising a microfluidic device in the present invention.
  • the devices herein optionally include signal detectors, e.g., which detect fluorescence, phosphorescence, radioactivity, pH, charge, absorbance, luminescence, temperature, magnetism or the like.
  • Fluorescent detection is especially preferred and generally used for detection of amplified nucleic acids, particularly for real-time PCR amplification (however, downstream operations can be performed on amplicons, which can involve other detection methods, such as mass spectroscopy or size exclusion).
  • the detector(s) optionally monitor one or a plurality of signals from an amplification reaction and/or hybridization reaction.
  • the detector can monitor optical signals which correspond to "real time" amplification assay results.
  • the detector can monitor a single type of signal, or, e.g., simultaneously monitor multiple different signals.
  • Example detectors include photomultiplier tubes, photodiodes, avalanche photodiodes, photoresistors, bolometers, microchannel plate detectors, CCD arrays (including intensified and electron multiplying CCD arrays), CMOS image sensors, and/or the like. Wavelength discrimination may be achieved through the use of multilayer dielectric interference filters, color absorptive filters, or by dispersion with diffractive and/or refractive optical elements.
  • Amplicons or other components which emit a detectable signal can be flowed past the detector, or, alternatively, the detector can move relative to the site of the amplification reaction (or, the detector can simultaneously monitor a number of spatial positions corresponding to channel regions, or microtiter wells e.g., as in a CCD array).
  • Detectors in the present invention can detect signals from probes associated with nucleic acids of the invention that flow into one or more detection regions, e.g., of a microfluidic device.
  • the detector can include or be operably linked to a computer (or other logic device), e.g., which has software for converting detector signal information into assay result information (e.g., presence of a nucleic acid of interest, the length of a nucleic acid of interest, proportions of nucleic acid of interest lengths, and/or correlations with disease states), or the like.
  • say result information e.g., presence of a nucleic acid of interest, the length of a nucleic acid of interest, proportions of nucleic acid of interest lengths, and/or correlations with disease states
  • Signals are optionally calibrated, e.g., by calibrating the microfluidic system by monitoring a signal from a known source. For example, signals can be calibrated against a reference light source, internal reference signals, or normalized for detection of positive signals over background.
  • a microfluidic system according to the present invention can also employ multiple different detection systems for monitoring signals in the system. Detection systems of the present invention are used to detect and monitor the materials in a particular channel region (or other reaction detection region). Once detected, the flow rate and velocity of any cells or droplets in the channels can be optionally measured by sensors and controlled as described above.
  • Examples of detection systems useful in methods and systems of the invention can include optical sensors, temperature sensors, pressure sensors, pH sensors, conductivity sensors, and the like. Each of these types of sensors is readily incorporated into the microfluidic systems described herein. In these systems, such detectors can be placed either within or adjacent to the microfluidic device or one or more channels, chambers or conduits of the device, such that the detector is within sensory communication with the device, channel, or chamber.
  • within sensory communication generally refers to the placement of the detector in a position such that the detector is capable of detecting the property of the microfluidic device, a portion of the microfluidic device, or the contents of a portion of the microfluidic device, for which that detector was intended.
  • a pH sensor placed in sensory communication with a microscale channel is capable of determining the pH of a fluid disposed in that channel.
  • a temperature sensor placed in sensory communication with the body of a microfluidic device is capable of determining the temperature of the device itself.
  • Preferred detection systems in accordance with the present invention include optical detection systems for detecting an optical property of a material within the channels and/or chambers of the microfluidic devices that are incorporated into the microfluidic systems described herein. Such optical detection systems are typically placed adjacent to a microscale channel of a microfluidic device, and are in sensory communication with the channel via an optical detection window that is disposed across the channel or chamber of the device. Optical detection systems include systems that are capable of measuring the light emitted from material within the channel, the transmissivity or absorbance of the material, as well as the materials spectral characteristics. In preferred aspects, the detector measures an amount of light emitted from the material, such as a fluorescent or chemiluminescent material.
  • the detection system will typically include collection optics for gathering a light based signal transmitted through the detection window, and transmitting that signal to an appropriate light detector.
  • Microscope objectives of varying power, field diameter, and focal length are readily utilized as at least a portion of this optical train.
  • the light detectors are optionally spectrophotometers, photodiodes, avalanche photodiodes, photomultiplier tubes, diode arrays, or in some cases, imaging systems, such as charged coupled devices (CCDs) and the like.
  • the detection system is typically coupled to a computer, via an analog to digital or digital to analog converter, for transmitting detected light data to the computer for analysis, storage and data manipulation.
  • the detector typically includes a light source that produces light at an appropriate wavelength for activating the fluorescent material, as well as optics for directing the light source through the detection window to the material contained in the channel or chamber.
  • the light source can be any number of light sources that provides an appropriate wavelength, including lasers and LEDs. Other light sources are used in other detection systems. For example, broad band light sources are typically used in light scattering/transmissivity detection schemes, and the like. Typically, light selection parameters are well known to those of skill in the art.
  • the detector can exist as a separate unit, but can also be integrated with the system or micro fluidic device, into a single instrument. Integration of these functions into a single unit facilitates connection of these instruments with the computer, by permitting the use of few or a single communication port(s) for transmitting information between the controller, the detector and the computer.
  • This correlation can be performed at the theoretical level, taking thermal diffusivity and Taylor Aris dispersion into account, or it can be performed by comparison to standards (e.g., comparisons to peak shapes, e.g., heights, widths, or general shape profiles for amplification reactions that have known copy numbers for starting materials).
  • the same or different peak parameters can be evaluated in interpretation of detector signals for two on more probes in determination of nucleic acid length.
  • the concentration profile along the channel may be approximated using a modified diffusion equation. See G.I. Taylor (Proc Roy Soc Lond A 219: 186(1953)) and R. Aris (Proc Roy Soc Lond A 235:67 (1956)).
  • the Taylor dispersion coefficient (D T ) is dependent on the dimensions and shape of the microfluidic cavity through which the marker is flowed, the average flow velocity (v) and the molecular diffusivity (D m ).
  • D T D n , (1 + k v 2 w 2 /D m 2 ), where w is a characteristic channel width and k is a dimensionless factor that depends on the shape of the channel cross-section.
  • fluid parameters and channel dimensions are chosen to reduce dispersion to an acceptable level.
  • the systems of the invention can include microfluidic devices, reaction mixtures, detectors, sample storage elements (microtiter plates, dried arrays of components, etc.), flow controllers, amplification devices or microfluidic modules, computers and/or the like. These systems can be used for aliquotting, amplifying and analyzing the nucleic acids of interest.
  • the microfluidic devices, amplification components, detectors and storage elements of the systems have already been described in some detail above. The following discussion describes appropriate controllers and computers, though many configurations are available and one of skill would be expected to be familiar in their use and would understand how they can be applied to the present invention.
  • a variety of controlling instrumentation is optionally utilized in conjunction with the microfluidic devices described herein, for controlling the transport and direction of fluids and/or materials within the devices of the present invention, e.g., by pressure-based or electrokinetic control.
  • fluid transport and direction are controlled in whole or in part, using pressure based flow systems that incorporate external or internal pressure sources to drive fluid flow.
  • Internal sources include microfabricated pumps, e.g., diaphragm pumps, thermal pumps, Lamb wave pumps and the like that have been described in the art. See, e.g., U.S. Pat. Nos. 5,271,724, 5,277,556, and 5,375,979 and PCT Published Patent Application Nos. WO 94/05414 and WO 97/02357.
  • the systems described herein can also utilize electrokinetic material direction and transport systems.
  • external pressure sources are used, and applied to ports at channel termini. These applied pressures, or vacuums, generate pressure differentials across the lengths of channels to drive fluid flow through them.
  • differential flow rates on volumes are optionally accomplished by applying different pressures or vacuums at multiple ports, or preferably, by applying a single vacuum at a common waste port and configuring the various channels with appropriate resistance to yield desired flow rates.
  • Example systems are described in U.S. Published Patent Application No. 2002/0019059.
  • the controller systems are appropriately configured to receive or interface with a microfluidic device or system element as described herein.
  • the controller and/or detector optionally includes a stage upon which a microfluidic device is mounted to facilitate appropriate interfacing between the controller and/or detector and the device.
  • the stage includes an appropriate mounting/alignment structural element, such as a nesting well, alignment pins and/or holes, asymmetric edge structures (to facilitate proper device alignment), and the like. Many such configurations are described in the references cited herein.
  • the controlling instrumentation discussed above is also optionally used to provide for electrokinetic injection or withdrawal of material downstream of the region of interest to control an upstream flow rate.
  • the same instrumentation and techniques described above are also utilized to inject a fluid into a downstream port to function as a flow control element.
  • either or both of the controller system and/or the detection system can be coupled to an appropriately programmed processor or computer (logic device) which functions to instruct the operation of these instruments in accordance with preprogrammed or user input instructions, receive data and information from these instruments, and interpret, manipulate and report this information to the user.
  • the computer is typically appropriately coupled to one or both of these instruments (e.g., including an analog to digital or digital to analog converter as needed), such as the main control and processing computer 105 illustrated in Figure 1.
  • the computer typically includes appropriate software for receiving user instructions, either in the form of user input into a set parameter fields, e.g., in a GUI, or in the form of preprogrammed instructions, e.g., preprogrammed for a variety of different specific operations.
  • the software then converts these instructions to appropriate language for instructing the operation of the fluid direction and transport controller to carry out the desired operation.
  • the computer then receives the data from the one or more sensors/detectors included within the system, and interprets the data, either provides it in a user understood format, or uses that data to initiate further controller instructions, in accordance with the programming, e.g., such as in monitoring and control of flow rates (including for continuous flow), temperatures, applied voltages, and the like.
  • the systems and/or kits can include system instructions (e.g., embodied in a computer or in a computer readable medium, e.g., as system software) for practicing any of the method steps herein.
  • the system optionally includes system software that correlates a shape, length, width, volume and/or area occupied by amplified copies of the nucleic acid of interest, as detected by the detector, to the number of copies of the nucleic acid of interest present in one of the aliquots, or to the number of copies of the nucleic acid of interest present in the sample, or both.
  • system optionally includes system instructions that direct the dilution module to aliquot the sample into a plurality of aliquots, including a plurality of zero copy aliquots comprising no copies of the nucleic acids of interest and one or more single copy aliquot comprising a single copy of the nucleic acid of interest.
  • the statistical functions noted above can also be incorporated into system software, e.g., embodied in the computer, in computer memory or on computer readable media.
  • the computer can include statistical or probabilistic system software that performs one or more statistical or probabilistic analysis of signals received from one or more of the aliquots subjected to amplification (e.g., via thermocycling).
  • the statistical or probabilistic analysis software optionally quantitatively determines a concentration, proportion, or number of the nucleic acids of interest in the sample.
  • Computers and software of the systems receive and evaluate signal data from one or more analyses to provide quantitation and/or proportionality determinations for nucleic acids of interest.
  • the amplitude or integrated area of a signal can be adjusted with a conversion factor for an output in desired units, such as, e.g., copies per nL, ng/ ⁇ L, and the like.
  • one or more standard materials of known concentration can be analyzed to provide data for regression analyses wherein changes in detectable signals with changes in concentration are expressed as an equation (standard curve) from which unknown concentrations can be determined by insertion of one or more signal parameters into the equation.
  • quantitation of a nucleic acid of interest can be based on the number of amplification cycles required to obtain a signal of a certain intensity.
  • the computer typically includes software for the monitoring of materials in the channels. Additionally, the software is optionally used to control electrokinetic or pressure modulated injection or withdrawal of material. The injection or withdrawal is used to modulate the flow rate as described above, to mix components, and the like.
  • the flow rate was approximately 1 mm per min with continuous flow in the microchannels during the experiment.
  • the real-time PCR system used in this experiment included an LED array with a 470 nm peak and a 630 nm peak an excitation filter and a dual bandpass interference filter.
  • the detector conditions were as follows: dectector: CMOS 12.8 Mpixel; lens: 50 mm f/1.4; magnification: approximately 1:1; emission filter: interference filter with passbands of 510 -565 nm and 660-71 Onm; ISO sensitivity: 3200. Simultaneous multi-color image acquisition was performed during the 72°C extension phase.
  • FIG. 8 A shows a 30 mm long section of the channels under continuous-flow PCR conditions. Red flow markers consisting of Alexa Fluor 647 dye boluses are visible. The green light, noticeable only at the downstream end of the channel on the right, is from SYBR Green 1 dye indicating the presence of amplified DNA.
  • Figure 8B shows a plot of the intensity of the red signal along microchannel 2 (second from the top) from Figure 8A.
  • FIG. 9A shows a 30 mm long section of the channels under continuous-flow PCR conditions.
  • the green light is from SYBR Green dye fluorescence acquired during the extension phase and indicates the presence of amplified DNA. In this case, no separate flow markers were injected into the channels.
  • Figure 9B shows a plot of the intensity of the green signal along microchannel 2 (second from the top) from Figure 9A.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Clinical Laboratory Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

la présente invention concerne des procédés d'amplification d'acides nucléiques dans des micro-canaux. L'invention concerne plus particulièrement des procédés pour effectuer une amplification en chaîne par polymérase (PCR) dans un système micro-fluidique à flux continu, et des procédés de surveillance de la PCR en temps réel dans de tels systèmes.
PCT/US2007/014863 2006-06-30 2007-06-27 Amplification en chaîne par polymérase en temps réel dans des micro-canaux WO2008005248A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07796482.3A EP2046988A4 (fr) 2006-06-30 2007-06-27 Amplification en chaîne par polymérase en temps réel dans des micro-canaux
JP2009518241A JP2009542210A (ja) 2006-06-30 2007-06-27 マイクロチャネル内のリアルタイムｐｃｒ

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80644006P 2006-06-30 2006-06-30
US60/806,440 2006-06-30
US11/505,358 2006-08-17
US11/505,358 US7629124B2 (en) 2006-06-30 2006-08-17 Real-time PCR in micro-channels

Publications (2)

Publication Number Publication Date
WO2008005248A2 true WO2008005248A2 (fr) 2008-01-10
WO2008005248A3 WO2008005248A3 (fr) 2008-07-31

Family

ID=38877102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/014863 WO2008005248A2 (fr) 2006-06-30 2007-06-27 Amplification en chaîne par polymérase en temps réel dans des micro-canaux

Country Status (1)

Country Link
WO (1) WO2008005248A2 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009232700A (ja) * 2008-03-26 2009-10-15 Shimadzu Corp 反応処理方法及び反応処理装置
JP2009268432A (ja) * 2008-05-09 2009-11-19 Canon Inc 標的核酸の測定方法
JP2010022315A (ja) * 2008-07-23 2010-02-04 Sony Corp 核酸量検出装置及び核酸量検出方法
WO2010118430A1 (fr) * 2009-04-10 2010-10-14 Canon U.S. Life Sciences, Inc. Procédé de fourniture d'une solution pcr a une chambre pcr microfluidique
WO2010141140A1 (fr) * 2009-06-04 2010-12-09 Lockheed Martin Corporation Approche optique pour la detection par electrophorese d'adn microfluidique
CN102220226A (zh) * 2011-05-23 2011-10-19 北京工业大学 双路温控聚合酶链式反应器与实时检测装置
WO2011130625A1 (fr) * 2010-04-16 2011-10-20 Claros Diagnostics, Inc. Asservissement dans des systèmes microfluidiques
WO2012154346A1 (fr) * 2011-04-08 2012-11-15 Stokes Bio Limited Système optique de point limite et procédé d'utilisation
WO2013113072A1 (fr) * 2012-02-03 2013-08-08 Axxin Pty Ltd Appareil et procédé d'amplification et de détection d'acide nucléique
EP2611942A4 (fr) * 2010-08-31 2015-01-14 Canon Us Life Sciences Inc Réglage de la position de barreaux de combustible pendant un cyclage thermique
US8961764B2 (en) 2010-10-15 2015-02-24 Lockheed Martin Corporation Micro fluidic optic design
EP2878374A1 (fr) * 2013-11-29 2015-06-03 IMEC vzw Dispositif et procédé pour effectuer une PCR numérique
US9322054B2 (en) 2012-02-22 2016-04-26 Lockheed Martin Corporation Microfluidic cartridge
US9932629B2 (en) 2012-06-26 2018-04-03 Axxin Pty Ltd Nucleic acid amplification and detection kit
US10463290B2 (en) 2014-11-14 2019-11-05 Axxin Pty Ltd. Biological sample collection and storage assembly
CN112925006A (zh) * 2019-12-05 2021-06-08 核工业西南物理研究院 一种磁约束装置聚变中子实时能谱解谱方法
US11198122B2 (en) 2015-07-17 2021-12-14 Axxin Pty Ltd Diagnostic test assembly, apparatus, method
CN114717296A (zh) * 2012-02-03 2022-07-08 加州理工学院 多路生化测定中信号的编码和解码
DE112015005826B4 (de) 2015-01-27 2023-01-26 Hitachi High-Tech Corporation Mehrfarbige-fluoreszenz-analysevorrichtung
US11709175B2 (en) 2017-09-27 2023-07-25 Axxin Pty Ltd Diagnostic test system and method utilizing a closure/sample dispensing mechanism to dispense a sample subvolume for testing

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100552706B1 (ko) * 2004-03-12 2006-02-20 삼성전자주식회사 핵산 증폭 방법 및 장치

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None
See also references of EP2046988A4

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009232700A (ja) * 2008-03-26 2009-10-15 Shimadzu Corp 反応処理方法及び反応処理装置
JP2009268432A (ja) * 2008-05-09 2009-11-19 Canon Inc 標的核酸の測定方法
JP2010022315A (ja) * 2008-07-23 2010-02-04 Sony Corp 核酸量検出装置及び核酸量検出方法
US20120107822A1 (en) * 2009-04-10 2012-05-03 Hiroshi Inoue Method of delivering pcr solution to microfluidic pcr chamber
WO2010118430A1 (fr) * 2009-04-10 2010-10-14 Canon U.S. Life Sciences, Inc. Procédé de fourniture d'une solution pcr a une chambre pcr microfluidique
US9630158B2 (en) * 2009-04-10 2017-04-25 Canon U.S. Life Sciences, Inc. Method of delivering PCR solution to microfluidic PCR chamber
AU2010257127B2 (en) * 2009-06-04 2014-09-11 Lockheed Martin Corporation Optical approach for microfluidic DNA electrophoresis detection
GB2484610A (en) * 2009-06-04 2012-04-18 Lockheed Corp Optical approach for microfluidic dna electrophoresis detection
US9656261B2 (en) 2009-06-04 2017-05-23 Leidos Innovations Technology, Inc. DNA analyzer
US9649631B2 (en) 2009-06-04 2017-05-16 Leidos Innovations Technology, Inc. Multiple-sample microfluidic chip for DNA analysis
WO2010141140A1 (fr) * 2009-06-04 2010-12-09 Lockheed Martin Corporation Approche optique pour la detection par electrophorese d'adn microfluidique
US9067207B2 (en) 2009-06-04 2015-06-30 University Of Virginia Patent Foundation Optical approach for microfluidic DNA electrophoresis detection
GB2484610B (en) * 2009-06-04 2014-04-09 Lockheed Corp Optical approach for microfluidic dna electrophoresis detection
EP2558202B1 (fr) * 2010-04-16 2024-06-05 Opko Diagnostics, LLC Asservissement dans des systèmes microfluidiques
US9643182B2 (en) 2010-04-16 2017-05-09 Opko Diagnostics, Llc Systems and devices for analysis of samples
US8765062B2 (en) 2010-04-16 2014-07-01 Opko Diagnostics, Llc Systems and devices for analysis of samples
US9981266B2 (en) 2010-04-16 2018-05-29 Opko Diagnostics, Llc Feedback control in microfluidic systems
US10456784B2 (en) 2010-04-16 2019-10-29 Opko Diagnostics, Llc Systems and devices for analysis of samples
US9682376B2 (en) 2010-04-16 2017-06-20 Opko Diagnostics, Llc Systems and devices for analysis of samples
WO2011130625A1 (fr) * 2010-04-16 2011-10-20 Claros Diagnostics, Inc. Asservissement dans des systèmes microfluidiques
CN102971076A (zh) * 2010-04-16 2013-03-13 欧普科诊断有限责任公司 微流体系统中的反馈控制
US9116124B2 (en) 2010-04-16 2015-08-25 Opko Diagnostics, Llc Feedback control in microfluidic systems
EA022356B1 (ru) * 2010-04-16 2015-12-30 Опкоу Дайагностикс, Ллк Способ управления средами в микрофлюидных системах с обратной связью
US11458473B2 (en) 2010-04-16 2022-10-04 Opko Diagnostics, Llc Systems and devices for analysis of samples
US9861985B2 (en) 2010-08-31 2018-01-09 Canon U.S. Life Sciences, Inc. Slug control during thermal cycling
EP2611942A4 (fr) * 2010-08-31 2015-01-14 Canon Us Life Sciences Inc Réglage de la position de barreaux de combustible pendant un cyclage thermique
US8961764B2 (en) 2010-10-15 2015-02-24 Lockheed Martin Corporation Micro fluidic optic design
US20160340715A1 (en) * 2011-04-08 2016-11-24 Stokes Bio Limited End-Point Optical System and Method of Use
US20140127701A1 (en) * 2011-04-08 2014-05-08 Stokes Bio Limited End-Point Optical System and Method of Use
WO2012154346A1 (fr) * 2011-04-08 2012-11-15 Stokes Bio Limited Système optique de point limite et procédé d'utilisation
CN103748453A (zh) * 2011-04-08 2014-04-23 斯多克斯生物有限公司 终点光学系统和使用方法
CN102220226A (zh) * 2011-05-23 2011-10-19 北京工业大学 双路温控聚合酶链式反应器与实时检测装置
WO2013113072A1 (fr) * 2012-02-03 2013-08-08 Axxin Pty Ltd Appareil et procédé d'amplification et de détection d'acide nucléique
US11634758B2 (en) 2012-02-03 2023-04-25 Axxin Pty Ltd Nucleic acid amplification and detection apparatus and method
US10428375B2 (en) 2012-02-03 2019-10-01 Axxin Pty Ltd Nucleic acid amplification and detection apparatus and method
US12168797B2 (en) 2012-02-03 2024-12-17 California Institute Of Technology Signal encoding and decoding in multiplexed biochemical assays
CN114717296A (zh) * 2012-02-03 2022-07-08 加州理工学院 多路生化测定中信号的编码和解码
US9988676B2 (en) 2012-02-22 2018-06-05 Leidos Innovations Technology, Inc. Microfluidic cartridge
US9322054B2 (en) 2012-02-22 2016-04-26 Lockheed Martin Corporation Microfluidic cartridge
US9932629B2 (en) 2012-06-26 2018-04-03 Axxin Pty Ltd Nucleic acid amplification and detection kit
EP2878374A1 (fr) * 2013-11-29 2015-06-03 IMEC vzw Dispositif et procédé pour effectuer une PCR numérique
US11266990B2 (en) 2013-11-29 2022-03-08 Imec Vzw Device and method for performing digital PCR
US10463290B2 (en) 2014-11-14 2019-11-05 Axxin Pty Ltd. Biological sample collection and storage assembly
DE112015005826B4 (de) 2015-01-27 2023-01-26 Hitachi High-Tech Corporation Mehrfarbige-fluoreszenz-analysevorrichtung
US11198122B2 (en) 2015-07-17 2021-12-14 Axxin Pty Ltd Diagnostic test assembly, apparatus, method
US11709175B2 (en) 2017-09-27 2023-07-25 Axxin Pty Ltd Diagnostic test system and method utilizing a closure/sample dispensing mechanism to dispense a sample subvolume for testing
CN112925006A (zh) * 2019-12-05 2021-06-08 核工业西南物理研究院 一种磁约束装置聚变中子实时能谱解谱方法

Also Published As

Publication number Publication date
WO2008005248A3 (fr) 2008-07-31

Similar Documents

Publication Publication Date Title
US10583442B2 (en) Real-time PCR in micro-channels
WO2008005248A2 (fr) Amplification en chaîne par polymérase en temps réel dans des micro-canaux
US7645581B2 (en) Determining nucleic acid fragmentation status by coincident detection of two labeled probes
US8275554B2 (en) System for differentiating the lengths of nucleic acids of interest in a sample
AU2003302770B2 (en) Single molecule amplification and detection of DNA
US20220008928A1 (en) Method of analysis
JP5743403B2 (ja) デジタル式マルチプレックスｐｃｒアッセイに関する機器及び方法
US20170144161A1 (en) Method of generating droplets
US20090143233A1 (en) Device and method for digital multiplex pcr assays
US20070231799A1 (en) Method and apparatus for applying continuous flow and uniform temperature to generate thermal melting curves in a microfluidic device

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07796482

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009518241

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2007796482

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007796482

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载